Ex Vivo Test of New Stroke Treatment Using Magnetic Nanorobots

Last updated: March 9, 2022
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thrombosis

Treatment

N/A

Clinical Study ID

NCT04644653
2020.384
  • Ages 20-45
  • Female
  • Accepts Healthy Volunteers

Study Summary

Tissue plasminogen activator (tPA) is the FDA approved thrombolytic drug for patients with acute ischemic stroke. While transcatheter endovascular therapy is widely accepted as an effective method for targeted blood vessels via a catheter to elicit ischemic necrosis.

To improve targeting accuracy administrated tPA and avoiding collateral tissue damage, we developed a magnetic nanorobotic system to active system to active intravenous delivery of tPA for targeted thrombus removal. Here human placenta will be used as an ex vivo model for human cerebral vascular system in our ex vivo thrombolysis study. Our magnetic nanorobotic system encapsulated with tPA overcomes the limitations of passive thrombolytic therapy with tPA alone and will be a promising approach for the treatment of ischemic stroke and other thrombotic diseases

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirthwith natural delivery or caesarean sections after 37-42 weeks of gestation.
  • Healthy singleton pregnancy.
  • Participant able to give voluntary, written, informed consent to participate in thestudy.

Exclusion

Exclusion Criteria:

  • Abnormal prenatal development (e.g intrauterine growth restriction)
  • Early preterm birth < 37 weeks
  • Verbal Confirmation of hypercholesterolemia
  • Family history of stroke or vascular disease
  • Type I or Type II diabetes and gestational diabetes
  • Cancer, except skin cancers completely excised with no chemotherapy or radiation witha follow up that is negative.
  • Clinically significant abnormal laboratory results at screening.
  • Any other active or unstable medical condition.
  • History of liver disease.
  • History of hypertension (including pre-eclampsia)

Study Design

Total Participants: 100
Study Start date:
September 01, 2020
Estimated Completion Date:
September 30, 2025

Connect with a study center

  • Advanced Nanomaterials & Microrobotics Laboratory, Room 202, William M.W Mong Engineering Building, CUHK and Room 508, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital

    Shatin, New Territories
    Hong Kong

    Site Not Available

  • Department of Obstetrics and Gynaecology, Prince of Wales Hospital

    Shatin, New Territories
    Hong Kong

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.